Screener
Immunome IMNM R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Collaboration revenue | — | $2,926 |
| Operating expenses: | ||
| Research and development | 46,381 | 36,872 |
| General and administrative | 12,950 | 10,690 |
| Total operating expenses | 59,331 | 47,562 |
| Loss from operations | (59,331) | (44,636) |
| Interest income | 5,492 | 2,996 |
| Net loss | $(53,839) | $(41,640) |
Item 1. Financial Statements.
FAQ
- What is Immunome's R&D?
- Immunome (IMNM) reported R&D of $46.38M in Q1 2026.
- How has Immunome's R&D changed year-over-year?
- Immunome's R&D increased by 25.8% year-over-year, from $36.87M to $46.38M.
- What is the long-term trend for Immunome's R&D?
- Over 4 years (2021 to 2025), Immunome's R&D has grown at a 88.3% compound annual growth rate (CAGR), from $14.11M to $177.29M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Immunome's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude